VCYT

Veracyte, Inc.

$44.79

+2.26% 2026-10-20

Health CareS&P 600

1M 3M 6M 1Y 2Y

VCYTSPY

+3.9%

+12.6%

-24.8%

+33.7%

YTD

+6.4%

+22.2%

Live chart

Loading live chart…

Grades vs sector

Momentum

62nd pct in sector

B-

12-1 return: +27.6%
Percentile within its GICS sector across the S&P 1500.

Growth

73rd pct in sector

B+

Revenue growth (YoY): +15.5%
Percentile within its GICS sector across the S&P 1500.

Value

26th pct in sector

D+

Forward E/P: 4.5% · EBITDA/EV: 3.8%
Percentile within its GICS sector across the S&P 1500.

Profitability

63rd pct in sector

B-

Profit margin: +20.4% · Return on equity: +8.8%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

Natera Gains 118.1% in a Year: What's Driving the Rally?

Zacks · Oct 15

Key stats

Market cap$3.6B

P/E (trailing)32.0

P/E (forward)23.0

52-week range29.45 – 60.91

Revenue growth (YoY, latest qtr)+15.5%

Dividend yield0.00%

Analyst consensusBuy (12)

Mean price target$58.42 (+30%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +1 (DCF counts double).

•DCF (base case)above the price by 9%

▼Forward P/E vs sector23.0x vs median 17.6x

▲Piotroski F-score8/9

▲Altman Z22.8 (safe)

▲Net debt / EBITDA-2.8x

▲Analyst target+30% (12 analysts)

Discounted cash flow

Bear

$32

-30%

growth 11% · disc. 14.0% · term. 2.0%

Base

$49

+9%

growth 18% · disc. 13.0% · term. 2.5%

Bull

$69

+55%

growth 22% · disc. 12.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 13% a year for 10 years.

Implied

+13%/yr

FCF, last 3 yrs

n/a

FCF, last 5 yrs

n/a

Revenue, last 3 yrs

+20%/yr

Revenue, last 5 yrs

+35%/yr

Same inputs as the DCF above: trailing free cash flow 0.2B, 13.0% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.95 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 54th pct

32.0×
pricier

Forward P/E

sector median 17.6× · 69th pct

23.0×
pricier

EV / EBITDA

sector median 15.8× · 81st pct

25.7×
pricier

Price / sales

sector median 3.1× · 74th pct

6.4×
pricier

Price / book

sector median 3.5× · 37th pct

2.6×
cheaper

FCF yield

sector median 4.1% · 55th pct

4.6%
cheaper

Forward EPS $1.95 vs trailing $1.40 (+39% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$250.0K

as of 2018-06-30

vs a year ago

–

YoY

× TTM revenue

0.00×

coverage

18-06

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

71.7%

Operating margin

18.8%

FCF margin

29.5%

Net margin

20.4%

Return on equity

8.2%

Return on invested capital

10.0%

Net debt / EBITDA

-2.8×

Current ratio

9.2×

Interest cover

470.1×

Cash conversion (OCF/NI)

1.6×

Piotroski F-score 8/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✓ Gross margin improved✓ Asset turnover improved

Altman Z-score 22.8 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$58

+30%

Analysts

Buy

Range

$44–$70

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$517.1M	$66.4M	$126.6M
2024	$445.8M	$24.1M	$63.8M
2023	$361.1M	$-74.4M	$34.3M
2022	$296.5M	$-36.6M	$-1.0M
2021	$219.5M	$-75.6M	$-37.0M
2020	$117.5M	$-34.9M	$-12.5M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +20.4%.

Earnings

Next report: 2026-11-04 · during market · EPS est 0.41

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-30	0.43	0.54	+25.1%
2026-05-05	0.33	0.52	+56.0%
2026-02-25	0.41	0.53	+29.8%
2025-11-04	0.32	0.51	+59.5%
2025-08-06	0.30	0.44	+48.5%
2025-05-07	0.20	0.31	+51.4%
2025-02-24	0.26	0.36	+40.0%
2024-11-06	0.17	0.33	+98.8%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$150.3M	+15.5%
2026-03-31	$139.1M	–
2025-12-31	$140.6M	–
2025-09-30	$131.9M	–
2025-06-30	$130.2M	–

Analyst actions

Freedom Capital Markets

2026-09-15 · main

Buy → Buy
PT $66

UBS

2026-09-09 · main

Buy → Buy
PT $65

Piper Sandler

2026-08-04 · main

Overweight → Overweight
PT $54

Stephens & Co.

2026-08-04 · main

Overweight → Overweight
PT $55

Morgan Stanley

2026-08-04 · main

Underweight → Underweight
PT $44

Canaccord Genuity

2026-08-03 · main

Hold → Hold
PT $50

Insider trades

Bhanji Muna

Director · 2026-10-19

SELL
$81.5K

Leite John

Global Chief Commercial Off · 2026-09-21

SELL
$160.6K

Holstein Jens

Director · 2026-09-14

SELL
$204.7K

Febbo Phillip G.

Chief Scientific & Med Officer · 2026-09-04

SELL
$446.3K

Febbo Phillip G.

Chief Scientific & Med Officer · 2026-09-04

SELL
$118.1K

Chambers Rebecca

Chief Financial Officer · 2026-09-04

SELL
$106.0K

Chambers Rebecca

Chief Financial Officer · 2026-09-04

SELL
$51.4K

Mcguire Annie

EVP, General Counsel · 2026-09-04

SELL
$92.2K

Mcguire Annie

EVP, General Counsel · 2026-09-04

SELL
$48.0K

Bhanji Muna

Director · 2026-09-01

SELL
$80.1K

None

None · None

SELL
–

None

None · None

SELL
–

Stats refreshed 2026-10-20 18:13:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status